CHADDS FORD, Pa. (AP) — Endo Pharmaceuticals Holdings Inc. will sell $400 million in debt to help pay for its
acquisition of Qualitest Pharmaceuticals.
Endo said the debt will be due in 2020 and will be sold in a private
placement. Endo announced in October that it would buy Qualitest for $1.2
billion. If the deal does not go through, Endo plans to use the proceeds from
the offering for general corporate purposes.
